Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a
Khorana score
adjuvant chemotherapy
colorectal cancer
thrombosis
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2020
2020
Historique:
received:
12
01
2019
accepted:
09
12
2019
entrez:
4
2
2020
pubmed:
6
2
2020
medline:
6
2
2020
Statut:
epublish
Résumé
The risk of venous thromboembolic events (VTE) during adjuvant chemotherapy for colorectal cancer (CRC) is unknown. We aim to evaluate if the Khorana score (KS) can predict this risk, and if it represents a prognostic factor for overall survival (OS) through a A logistic regression model was used to test the associations between the risk of VTE and the KS. The results are expressed as odds ratios (OR) with 95% confidence intervals (95% CI). To assess the effect of the KS on OS, multivariable analyses using Cox regression models were performed. The results are expressed as hazard ratios (HR) with 95% CI. Among 1380 CRC patients with available data, the VTE risk ( The use of the KS did not predict VTEs in a low-moderate thromboembolic risk population as CRC. These data did not support the use of KS to predict VTE during adjuvant chemotherapy, and suggest that other risk assessment models should be researched.
Sections du résumé
BACKGROUND
BACKGROUND
The risk of venous thromboembolic events (VTE) during adjuvant chemotherapy for colorectal cancer (CRC) is unknown. We aim to evaluate if the Khorana score (KS) can predict this risk, and if it represents a prognostic factor for overall survival (OS) through a
METHODS
METHODS
A logistic regression model was used to test the associations between the risk of VTE and the KS. The results are expressed as odds ratios (OR) with 95% confidence intervals (95% CI). To assess the effect of the KS on OS, multivariable analyses using Cox regression models were performed. The results are expressed as hazard ratios (HR) with 95% CI.
RESULTS
RESULTS
Among 1380 CRC patients with available data, the VTE risk (
CONCLUSIONS
CONCLUSIONS
The use of the KS did not predict VTEs in a low-moderate thromboembolic risk population as CRC. These data did not support the use of KS to predict VTE during adjuvant chemotherapy, and suggest that other risk assessment models should be researched.
Identifiants
pubmed: 32010236
doi: 10.1177/1758835919899850
pii: 10.1177_1758835919899850
pmc: PMC6974756
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1758835919899850Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
JAMA. 2008 Nov 19;300(19):2277-85
pubmed: 19017914
Ann Surg. 2012 May;255(5):963-70
pubmed: 22504195
Blood. 2008 May 15;111(10):4902-7
pubmed: 18216292
J Clin Oncol. 2018 May 20;36(15):1478-1485
pubmed: 29620994
BMC Cancer. 2017 Jun 15;17(1):415
pubmed: 28619086
Cancer. 2005 Dec 15;104(12):2822-9
pubmed: 16284987
Thromb Haemost. 2017 Jun 2;117(6):1192-1198
pubmed: 28276571
Oncologist. 2017 Oct;22(10):1222-1231
pubmed: 28550032
Oncologist. 2016 Jul;21(7):861-7
pubmed: 27125754
N Engl J Med. 2012 Feb 16;366(7):601-9
pubmed: 22335737
Ann Oncol. 2010 Apr;21(4):871-6
pubmed: 19713246
Ann Oncol. 2016 Nov;27(11):2074-2081
pubmed: 27573560
Cochrane Database Syst Rev. 2012 Feb 15;(2):CD008500
pubmed: 22336844
Haematologica. 2019 Jun;104(6):1277-1287
pubmed: 30606788
Oncologist. 2013;18(12):1321-9
pubmed: 24212499
Oncologist. 2012;17(9):1191-7
pubmed: 22767876
World J Gastrointest Oncol. 2017 Sep 15;9(9):363-371
pubmed: 28979718
Blood. 2013 Sep 5;122(10):1712-23
pubmed: 23908465
J Clin Oncol. 2012 Dec 10;30(35):4416-26
pubmed: 23150697